liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study)
University of Calif San Diego, CA 92103 USA.
University of Calif San Diego, CA 92103 USA.
University of Groningen, Netherlands.
University of Groningen, Netherlands.
Show others and affiliations
2014 (English)In: American Journal of Cardiology, ISSN 0002-9149, E-ISSN 1879-1913, Vol. 114, no 5, 737-742 p.Article in journal (Refereed) Published
Abstract [en]

The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy. were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.

Place, publisher, year, edition, pages
Elsevier , 2014. Vol. 114, no 5, 737-742 p.
National Category
URN: urn:nbn:se:liu:diva-111271DOI: 10.1016/j.amjcard.2014.05.062ISI: 000341333600013PubMedID: 25129066OAI: diva2:755556

Funding Agencies|Netherlands Heart Foundation [2000Z003]; Roche Diagnostics Nederland BV, Venlo, The Netherlands (NT-proBNP)

Available from: 2014-10-14 Created: 2014-10-14 Last updated: 2016-06-05

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jaarsma, Tiny
By organisation
Division of Health, Activity and CareFaculty of Health Sciences
In the same journal
American Journal of Cardiology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 262 hits
ReferencesLink to record
Permanent link

Direct link